$NPCE
NeuroPace Inc Stock $npce

$npce Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000152828721000006 Filed on June 03, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$11.22M	$9.975M
YoY Change	12.45%
Cost Of Revenue	$2.724M	$2.918M
YoY Change	-6.65%
Gross Profit	$8.493M	$7.057M
YoY Change	20.35%
Gross Profit Margin	75.72%	70.75%
Selling, General & Admin	$8.267M	$7.682M
YoY Change	7.62%
% of Gross Profit	97.34%	108.86%
Research & Development	$4.100M	$4.833M
YoY Change	-15.17%
% of Gross Profit	48.28%	68.49%
Depreciation & Amortization	$100.0K	$100.0K
YoY Change	0.0%
% of Gross Profit	1.18%	1.42%
Operating Expenses	$12.37M	$12.52M
YoY Change	-1.18%
Operating Profit	-$3.874M	-$5.458M
YoY Change	-29.02%
Interest Expense	$1.849M	$2.998M
YoY Change	-38.33%
% of Operating Profit
Other Income/Expense, Net	-$3.113M	$1.715M
YoY Change	-281.52%
Pretax Income	-$8.810M
YoY Change
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$8.810M	-$6.741M
YoY Change	30.69%
Net Earnings / Revenue	-78.54%	-67.58%
Basic Earnings Per Share	-$32.73	-$33.32
Diluted Earnings Per Share	-$32.73	-$33.32
COMMON SHARES
Basic Shares Outstanding	269.2K shares	202.3K shares
Diluted Shares Outstanding	269.2K shares	202.3K shares

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$30.53M
YoY Change
Cash & Equivalents	$13.84M	$9.624M
Short-Term Investments	$16.69M
Other Short-Term Assets	$1.314M
YoY Change
Inventory	$7.042M
Prepaid Expenses
Receivables	$8.202M
Other Receivables	$0.00
Total Short-Term Assets	$47.09M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment	$476.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$23.00K
YoY Change
Total Long-Term Assets	$3.236M
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$47.09M
Total Long-Term Assets	$3.236M
Total Assets	$50.32M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.484M
YoY Change
Accrued Expenses	$5.734M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00
YoY Change
Long-Term Debt Due	$3.590M
YoY Change
Total Short-Term Liabilities	$10.81M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt	$49.56M
YoY Change
Other Long-Term Liabilities	$274.0K
YoY Change
Total Long-Term Liabilities	$49.84M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.81M
Total Long-Term Liabilities	$49.84M
Total Liabilities	$65.34M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings	-$396.5M
YoY Change
Common Stock	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$156.4M	-$135.8M
YoY Change
Total Liabilities & Shareholders Equity	$50.32M
YoY Change

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$8.810M	-$6.741M
YoY Change	30.69%
Depreciation, Depletion And Amortization	$100.0K	$100.0K
YoY Change	0.0%
Cash From Operating Activities	-$5.900M	-$6.500M
YoY Change	-9.23%
INVESTING ACTIVITIES
Capital Expenditures	$35.00K	$16.00K
YoY Change	118.75%
Acquisitions
YoY Change
Other Investing Activities	-$5.000M
YoY Change
Cash From Investing Activities	-$5.035M	-$471.0K
YoY Change	969.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$1.578M	$12.52M
YoY Change	-112.6%
NET CHANGE
Cash From Operating Activities	-$5.900M	-$6.500M
Cash From Investing Activities	-$5.035M	-$471.0K
Cash From Financing Activities	-$1.578M	$12.52M
Net Change In Cash	-$12.55M	$5.501M
YoY Change	-328.12%
FREE CASH FLOW
Cash From Operating Activities	-$5.900M	-$6.500M
Capital Expenditures	$35.00K	$16.00K
Free Cash Flow	-$5.935M	-$6.516M
YoY Change	-8.92%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001528287
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0100
CY2018Q2	npce	Operating Lease Renewal Term OperatingLeaseRenewalTerm	P5Y
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	001-40337
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	NEUROPACE, INC.
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	22-3550230
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	455 N. Bernardo Avenue
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Mountain View
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94043
CY2021Q1	dei	City Area Code CityAreaCode	650
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	237-2700
CY2021Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2021Q1	dei	Trading Symbol TradingSymbol	NPCE
CY2021Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	24291134	shares
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13841000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26390000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	16689000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	11689000	USD
CY2021Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8202000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8395000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	7042000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	6909000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1314000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1179000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	47088000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	54562000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	476000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	515000	USD
CY2021Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	366000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	366000	USD
CY2021Q1	us-gaap	Deferred Costs DeferredCosts	2371000	USD
CY2020Q4	us-gaap	Deferred Costs DeferredCosts	484000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	23000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	23000	USD
CY2021Q1	us-gaap	Assets Assets	50324000	USD
CY2020Q4	us-gaap	Assets Assets	55950000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1484000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	949000	USD
CY2021Q1	npce	Accrued And Employee Related Liabilities Current AccruedAndEmployeeRelatedLiabilitiesCurrent	5734000	USD
CY2020Q4	npce	Accrued And Employee Related Liabilities Current AccruedAndEmployeeRelatedLiabilitiesCurrent	6603000	USD
CY2021Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	3590000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2043000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	10808000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9595000	USD
CY2021Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1204000	USD
CY2020Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1301000	USD
CY2021Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	49561000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	50821000	USD
CY2021Q1	npce	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	3491000	USD
CY2020Q4	npce	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	369000	USD
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	274000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	274000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	65338000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	62360000	USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	60757386	shares
CY2021Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	60757386	shares
CY2021Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	16614178	shares
CY2020Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	16614178	shares
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	16614178	shares
CY2021Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	16614178	shares
CY2020Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	227755000	USD
CY2021Q1	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	227755000	USD
CY2021Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	141422000	USD
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	141422000	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	74636348	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	74636348	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	470634	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	470634	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	314096	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	314096	shares
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	240032000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	239826000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	33000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	33000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-396501000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-387691000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-156436000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-147832000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	50324000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	55950000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11217000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9975000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2724000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2918000	USD
CY2021Q1	us-gaap	Gross Profit GrossProfit	8493000	USD
CY2020Q1	us-gaap	Gross Profit GrossProfit	7057000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4100000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4833000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8267000	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7682000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	12367000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	12515000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3874000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5458000	USD
CY2021Q1	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	0	USD
CY2020Q1	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	461000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	1849000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	2998000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3087000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1715000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-8810000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-6741000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-41000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8810000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6782000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-32.73
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-32.73
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-33.32
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-33.32
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	269178	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	269178	shares
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	202341	shares
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	202341	shares
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	16614178	shares
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	141422000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-147832000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-8810000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	202000	USD
CY2021Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	16614178	shares
CY2021Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	141422000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-156436000	USD
CY2019Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	635048	shares
CY2019Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	73568000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-129350000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-6741000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-41000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	301000	USD
CY2020Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	635048	shares
CY2020Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	73568000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	-135825000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-8810000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-6741000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	202000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	301000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	74000	USD
CY2020Q1	us-gaap	Depreciation Depreciation	82000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	69000	USD
CY2020Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	72000	USD
CY2021Q1	npce	Increase Decrease In Non Cash Interest Expense IncreaseDecreaseInNonCashInterestExpense	217000	USD
CY2020Q1	npce	Increase Decrease In Non Cash Interest Expense IncreaseDecreaseInNonCashInterestExpense	1560000	USD
CY2021Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
CY2020Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	1350000	USD
CY2021Q1	us-gaap	Inventory Write Down InventoryWriteDown	24000	USD
CY2020Q1	us-gaap	Inventory Write Down InventoryWriteDown	97000	USD
CY2021Q1	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	0	USD
CY2020Q1	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-15000	USD
CY2021Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	3122000	USD
CY2020Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2021Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0	USD
CY2020Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-1705000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-194000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	197000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	157000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-349000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	135000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-144000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	536000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-109000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1094000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1692000	USD
CY2021Q1	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-178000	USD
CY2020Q1	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-74000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5936000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6548000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	35000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16000	USD
CY2021Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	0	USD
CY2021Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	5000000	USD
CY2020Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	6300000	USD
CY2020Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	6755000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5035000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-471000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6000	USD
CY2021Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1582000	USD
CY2020Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2021Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
CY2020Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	11867000	USD
CY2021Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2020Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	12514000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1578000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12520000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12549000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5501000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26756000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4123000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14207000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9624000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13841000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9624000	USD
CY2021Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	366000	USD
CY2020Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14207000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9624000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	1563000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2021Q1	npce	Unpaid Deferred Offering Costs UnpaidDeferredOfferingCosts	578000	USD
CY2020Q1	npce	Unpaid Deferred Offering Costs UnpaidDeferredOfferingCosts	0	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-8800000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-6700000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5900000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6500000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-396500000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	30500000	USD
CY2021Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited interim condensed financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. The Company uses significant judgment when making estimates related to the valuation of its common stock and related stock-based compensation, the valuation of deferred tax assets and related valuation allowances, </span></div>provision for excess and obsolete inventories, the valuation of derivative financial instruments and redeemable convertible preferred stock warrant liability. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.
CY2021Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk, and Other Risks and Uncertainties</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, short-term investments and accounts receivable to the extent of the amounts recorded on the balance sheet. The Company’s cash is invested in one major financial institution in the United States. Deposits in this financial institution may exceed federally insured limits. The Company’s cash equivalents are invested in money market funds.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s accounts receivable are due from a variety of health care organizations in the United States. For the three months ended March 31, 2021 and 2020, there were no customers that represented 10% or more of revenue. As of March 31, 2021 and December 31, 2020, no customer represented 10% or more of the Company’s accounts receivable.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed for expanded indications. There can be no assurance that the Company’s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence upon third-party payors to provide adequate coverage and reimbursement, dependence on key personnel, single-source suppliers and vendors in connection with the manufacture of its products, concentration of Level 4 CECs, obtaining, maintaining, protecting, enforcing, and defending intellectual property rights and proprietary technology, product liability claims, and compliance with government regulations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s medical devices require approvals or clearances from the U.S. Food and Drug Administration, or the FDA, or international regulatory agencies. In addition, in order to continue the Company’s operations, compliance with various federal and state laws is required. If approvals or clearances were withdrawn by the FDA for the Company’s current products or if such approvals or clearances were denied or delayed for future products, product updates, or expanded indications for use, it would have a material adverse impact on the Company.</span></div>
CY2021Q1	us-gaap	Deferred Costs DeferredCosts	2400000	USD
CY2020Q4	us-gaap	Deferred Costs DeferredCosts	500000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	5088000	USD
CY2021Q1	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	16689000	USD
CY2021Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	3491000	USD
CY2021Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	21777000	USD
CY2021Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	3491000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	5062000	USD
CY2020Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	11689000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	16751000	USD
CY2020Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	369000	USD
CY2020Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	369000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	16656000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	11656000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	33000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	33000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	16689000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	11689000	USD
CY2021Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	1823000	USD
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1721000	USD
CY2021Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	1532000	USD
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1487000	USD
CY2021Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3687000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3701000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	7042000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	6909000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8711000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8676000	USD
CY2021Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8235000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8161000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	476000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	515000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	100000	USD
CY2020Q1	us-gaap	Depreciation Depreciation	100000	USD
CY2021Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3708000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4565000	USD
CY2021Q1	npce	Accrued Inventory Liability Current AccruedInventoryLiabilityCurrent	471000	USD
CY2020Q4	npce	Accrued Inventory Liability Current AccruedInventoryLiabilityCurrent	636000	USD
CY2021Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	641000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	279000	USD
CY2021Q1	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	585000	USD
CY2020Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	666000	USD
CY2021Q1	npce	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	36000	USD
CY2020Q4	npce	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	107000	USD
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	293000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	350000	USD
CY2021Q1	npce	Accrued And Employee Related Liabilities Current AccruedAndEmployeeRelatedLiabilitiesCurrent	5734000	USD
CY2020Q4	npce	Accrued And Employee Related Liabilities Current AccruedAndEmployeeRelatedLiabilitiesCurrent	6603000	USD
CY2020Q2	npce	Operating Lease Percent Rental Payment Deferred OperatingLeasePercentRentalPaymentDeferred	0.500
CY2020Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	300000	USD
CY2020Q4	npce	Operating Lease Deferred Rent Interest Rate Annual Rate OperatingLeaseDeferredRentInterestRateAnnualRate	0.080
CY2021Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	700000	USD
CY2020Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	700000	USD
CY2021Q1	us-gaap	Deferred Rent Credit DeferredRentCredit	1800000	USD
CY2020Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	2000000.0	USD
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	2632000	USD
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	3172000	USD
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	3267000	USD
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	1666000	USD
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	10737000	USD
CY2020Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.125
CY2020Q3	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.1608
CY2021Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	60757386	shares
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	60757386	shares
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	16614178	shares
CY2020Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	16614178	shares
CY2021Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	16614178	shares
CY2021Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	16614178	shares
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	141422000	USD
CY2021Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	141422000	USD
CY2021Q1	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	227755000	USD
CY2020Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	227755000	USD
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P9Y18D
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2829317	shares
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	74636348	shares
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	20458842	shares
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	20615380	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	668299	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	818889	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2835265	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.03
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y6M25D
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	188361	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	188361	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.04
CY2021Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	156538	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.03
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	37771	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	37771	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.03
CY2021Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y4M24D
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2829317	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.09
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y5M26D
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	450358	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.03
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	0.03
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P9Y5M26D
CY2021Q1	npce	Share Based Compensation Arrangement By Share Based Payment Award Options Subject To Repurchase ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase	182316	shares
CY2020Q4	npce	Share Based Compensation Arrangement By Share Based Payment Award Options Subject To Repurchase ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase	30802	shares
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	202000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	301000	USD
CY2021Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	2000000.0	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-8810000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-6741000	USD
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	269178	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	269178	shares
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	202341	shares
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	202341	shares
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-32.73
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-32.73
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-33.32
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-33.32
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19972634	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	811492	shares

Files In Submission

Name	View Source	Status
0001528287-21-000006-index-headers.html	Edgar Link	pending
0001528287-21-000006-index.html	Edgar Link	pending
0001528287-21-000006.txt	Edgar Link	pending
0001528287-21-000006-xbrl.zip	Edgar Link	pending
exhibit311-certifications.htm	Edgar Link	pending
exhibit312certifications.htm	Edgar Link	pending
exhibit321certifications.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
npce-20210331.htm	Edgar Link	pending
npce-20210331.xsd	Edgar Link	pending
npce-20210331_cal.xml	Edgar Link	unprocessable
npce-20210331_def.xml	Edgar Link	unprocessable
npce-20210331_htm.xml	Edgar Link	completed
npce-20210331_lab.xml	Edgar Link	unprocessable
npce-20210331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NPCE
NeuroPace Inc Stock $npce

2021 Q1 Form 10-Q Financial Statement

#000152828721000006 Filed on June 03, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NPCE NeuroPace Inc Stock $npce

2021 Q1 Form 10-Q Financial Statement

#000152828721000006 Filed on June 03, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NPCE
NeuroPace Inc Stock $npce